UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

Temperature and Co thickness dependent sign change of the anomalous Hall effect in Co/Pd multilayers: An experimental and theoretical study

Applied physics letters, 2013-01, Vol.102 (2)

2013

Volltextzugriff (PDF)

Effect of doping and disorder on the half metallicity of full Heusler alloys

Applied physics letters, 2006-07, Vol.89 (4), p.042502-042502-3

2006

Volltextzugriff (PDF)

Ferromagnetic resonance in double perovskite epitaxial thin films of La2NiMnO6 on SrTiO3 and NdGaO3 substrates

Applied physics letters, 2010-08, Vol.97 (7)

2010

Volltextzugriff (PDF)

Comment on “Ferromagnetic wire lattice with a tunable negative index of refraction for microwaves using an external magnetic field” by Yun-Song Zhou et al

Europhysics letters, 2007-03, Vol.77 (6), p.64006

Aktaş, B.

2007

Volltextzugriff (PDF)

Defects in CrAs and related compounds as a route to half-metallic ferrimagnetism

Physical review. B, Condensed matter and materials physics, 2006-10, Vol.74 (14), Article 140408

2006

Volltextzugriff (PDF)

Spin-Peierls state versus Néel state in doped CuGeO3

Physical review letters, 1995-02, Vol.74 (8), p.1450-1453

1995

Volltextzugriff (PDF)

Monitoring of Clopidogrel Action: Comparison of Methods

Clinical chemistry (Baltimore, Md.), 2005-06, Vol.51 (6), p.957-965

2005

Volltextzugriff (PDF)

Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-01-09

2017

Volltextzugriff (PDF)

Abstract PD3-02: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD3-02-PD3-02

2018

Volltextzugriff (PDF)

Abstract P2-09-15: A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-09-15

2017

Volltextzugriff (PDF)

Abstract P2-02-01: In primary breast cancer patients with HER2-negative tumors, HER2-positive circulating tumor cells with stem cell character predict worse outcome

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-02-01

2016

Volltextzugriff (PDF)

Abstract P1-11-01: Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with advanced breast cancer (aBC)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-11-01

2018

Volltextzugriff (PDF)

Abstract P2-02-15: Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-02-15

2018

Volltextzugriff (PDF)

Abstract P2-03-09: Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-03-09

2017

Volltextzugriff (PDF)

Abstract P6-13-02: Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (aBC): Subgroup analyses of the German AVANTI observational study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-13-02

2017

Volltextzugriff (PDF)

Abstract P2-10-03: Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-10-03

2018

Volltextzugriff (PDF)

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS5-06-GS5-06

2019

Volltextzugriff (PDF)

Abstract P6-13-06: Novel combination therapies for triple negative breast cancer identified by high-throughput screening

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-13-06

2016

Volltextzugriff (PDF)

Abstract OT3-04-02: DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT3-04-02-OT3-04-02

2017

Volltextzugriff (PDF)

Abstract OT1-02-04: The DETECT V-study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-02-04-OT1-02-04

2017

Volltextzugriff (PDF)

Abstract P4-13-26: Efficacy, safety, and treatment decision-making in the AVANTI German observational study of first-line bevacizumab (BEV)-containing therapy for locally advanced, recurrent, or metastatic breast cancer (aBC)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P4-P4-13-26

2016

Volltextzugriff (PDF)

Abstract P4-14-04: AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-14-04

2013

Volltextzugriff (PDF)

Abstract P1-04-13: The role of excision repair cross-complementation 1 enzyme (ERCC1)-positive circulating tumor cells in primary and metastatic breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P1-P1-04-13

2013

Volltextzugriff (PDF)

Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS3-05-GS3-05

2018

Volltextzugriff (PDF)

Abstract P2-02-02: Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-02-02

2016

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(134)

Publikationsform

Artikel
(143)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(47)
Physics
(27)
Life Sciences & Biomedicine
(23)
Physical Sciences
(22)
Humans
(19)
Female
(14)
Animals
(11)
Biological And Medical Sciences
(11)
Physics, Applied
(11)
Medical Sciences
(9)
Physics, Multidisciplinary
(9)
Male
(7)
Materials Science
(7)
Mice
(6)
Risk Factors
(6)
Technology
(6)
Materials Science, Multidisciplinary
(5)
Physics, Condensed Matter
(5)
Exact Sciences And Technology
(4)
Fundamental And Applied Biological Sciences. Psychology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Temperature and Co thickness dependent sign change of the anomalous Hall effect in Co/Pd multilayers: An experimental and theoretical study

Effect of doping and disorder on the half metallicity of full Heusler alloys

Ferromagnetic resonance in double perovskite epitaxial thin films of La2NiMnO6 on SrTiO3 and NdGaO3 substrates

Comment on “Ferromagnetic wire lattice with a tunable negative index of refraction for microwaves using an external magnetic field” by Yun-Song Zhou et al

Defects in CrAs and related compounds as a route to half-metallic ferrimagnetism

Spin-Peierls state versus Néel state in doped CuGeO3

Monitoring of Clopidogrel Action: Comparison of Methods

Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients

Abstract PD3-02: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients

Abstract P2-09-15: A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy

Abstract P2-02-01: In primary breast cancer patients with HER2-negative tumors, HER2-positive circulating tumor cells with stem cell character predict worse outcome

Abstract P1-11-01: Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with advanced breast cancer (aBC)

Abstract P2-02-15: Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer

Abstract P2-03-09: Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls

Abstract P6-13-02: Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (aBC): Subgroup analyses of the German AVANTI observational study

Abstract P2-10-03: Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

Abstract P6-13-06: Novel combination therapies for triple negative breast cancer identified by high-throughput screening

Abstract OT3-04-02: DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancer

Abstract OT1-02-04: The DETECT V-study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Abstract P4-13-26: Efficacy, safety, and treatment decision-making in the AVANTI German observational study of first-line bevacizumab (BEV)-containing therapy for locally advanced, recurrent, or metastatic breast cancer (aBC)

Abstract P4-14-04: AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer

Abstract P1-04-13: The role of excision repair cross-complementation 1 enzyme (ERCC1)-positive circulating tumor cells in primary and metastatic breast cancer

Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

Abstract P2-02-02: Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer

Aktive Filter

Suchergebnisse filtern